Experimental Sleep Apnea Pill Reduced Breathing Disruptions By 44% In Trial

Nearly 1 billion people worldwide are affected by sleep apnea, and the condition often impacts not only patients themselves but also their bed partners. The most common form, obstructive sleep apnea (OSA), is characterized by repeated pauses or reductions in breathing during sleep that disrupt rest and place significant strain on the body.

In the short term, untreated sleep apnea may cause daytime fatigue, headaches, and loud snoring. Over time, it can increase the risk of hypertension, cardiovascular disease, stroke, type 2 diabetes, and cognitive decline, making effective treatment an important public health priority.

A Potential Alternative to CPAP

Continuous positive airway pressure (CPAP) remains the standard treatment for obstructive sleep apnea. The therapy delivers pressurized air through a mask to keep the airway open during sleep.

Although CPAP is highly effective when used consistently, many patients find it noisy, uncomfortable, or inconvenient, leading to poor adherence or discontinuation.

Patrick John Strollo, a sleep medicine specialist at the University of Pittsburgh Medical Center, notes that many diagnosed patients remain untreated or undertreated. According to Strollo, an oral medication targeting upper airway muscle control could potentially help address this major treatment gap.

How the AD109 Trial Was Conducted

Strollo and colleagues recently completed a phase 3 clinical trial evaluating a nightly oral medication called AD109 in adults with mild to severe obstructive sleep apnea.

The study included 646 participants from the United States and Canada, all of whom had previously rejected or were unable to tolerate CPAP therapy.

Participants were randomly assigned to receive either AD109 or a placebo while remaining blinded to treatment allocation. The medication was taken nightly for 26 weeks, beginning with a half-dose during the first week.

Researchers monitored changes in sleep apnea severity and clinical symptoms throughout the study.

Significant Reduction in Breathing Disruptions

The primary outcome measure was the apnea-hypopnea index (AHI), which quantifies breathing pauses and shallow breathing episodes per hour of sleep. AHI is the standard clinical measure used to classify sleep apnea severity.

Patients receiving AD109 experienced an average reduction in AHI of approximately 44% during the study period, compared with an approximately 18% reduction in the placebo group.

By week 26, nearly 42% of treated participants had improved sufficiently to move into a lower severity category.

Notably, almost 18% of participants receiving AD109 no longer met the diagnostic criteria for obstructive sleep apnea at the end of the trial.

These improvements were accompanied by favorable changes in additional clinical measures, suggesting meaningful benefits for daily functioning and symptom burden.

How the Sleep Apnea Pill Works

AD109 combines two existing medications with established safety profiles:

• atomoxetine, commonly prescribed for attention-deficit/hyperactivity disorder (ADHD);

• aroxybutynin, which suppresses certain parasympathetic nervous system signals.

Together, the drugs target neural pathways involved in controlling upper airway muscles during sleep.

An accompanying scientific review explains that the combination is designed to counter reduced noradrenergic signaling and REM sleep-related inhibition at the hypoglossal motor nucleus. In practical terms, this helps prevent upper airway collapse when muscle tone naturally decreases during sleep.

Reported side effects were generally mild and included dry mouth, nausea, and insomnia, consistent with the known effects of the component medications.

Researchers reported no unexpected safety concerns during the 26-week treatment period.

Regulatory Path and Broader Context

The US Food and Drug Administration (FDA) has granted AD109 fast-track designation, a status intended for therapies addressing unmet medical needs.

A regulatory decision is currently anticipated in 2027, pending full evaluation of the drug’s efficacy and safety data.

AD109 is part of a broader effort to develop alternatives to CPAP therapy. Other ongoing clinical trials are investigating repurposed epilepsy medications and GLP-1 receptor agonists used for obesity treatment, particularly for patients whose sleep apnea is associated with excess body weight.

Additional experimental approaches include implantable devices that stimulate tongue or airway muscles, as well as noninvasive techniques designed to strengthen upper airway function.

However, a once-daily oral therapy may prove particularly attractive because of its simplicity and ease of use.

According to Strollo, the findings support the concept that targeting neuromuscular dysfunction in obstructive sleep apnea can produce clinically meaningful improvements. If approved, AD109 could eventually provide millions of patients with a new treatment option that does not rely on masks or mechanical devices.